In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house executive to lead the surge. | Suarez will return to the U.S. as SVP and ...

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill Nereus. The decision came 15 months after the ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

Novo took its message to the people by setting up an exhibit at New York’s Grand Central Terminal. In a major thoroughfare at ...

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA ...

The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...

Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...